Histogenics Corp (NASDAQ:HSGX)’s share price fell 0.3% during trading on Monday . The stock traded as low as $0.52 and last traded at $0.55. 16,621 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 8,245,490 shares. The stock had previously closed at $0.55.
Several research firms recently commented on HSGX. Zacks Investment Research lowered Histogenics from a “hold” rating to a “sell” rating in a research note on Wednesday. Brookline Cap M reiterated a “buy” rating on shares of Histogenics in a research note on Wednesday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $3.50 target price on shares of Histogenics in a research note on Monday, August 13th. BTIG Research lowered Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 target price for the company. in a research note on Wednesday, September 5th. Finally, Needham & Company LLC boosted their price target on Histogenics to $5.00 and gave the company a “buy” rating in a research report on Thursday, September 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. Histogenics presently has a consensus rating of “Hold” and a consensus price target of $3.45.
The stock has a market cap of $16.12 million, a PE ratio of -0.57 and a beta of 1.02.
A number of hedge funds have recently bought and sold shares of the business. DRW Securities LLC purchased a new stake in Histogenics during the second quarter valued at about $242,000. Renaissance Technologies LLC grew its position in Histogenics by 6.1% during the second quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock valued at $961,000 after acquiring an additional 22,133 shares during the period. BlackRock Inc. grew its position in Histogenics by 72.0% during the second quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 22,927 shares during the period. Finally, JPMorgan Chase & Co. purchased a new stake in Histogenics during the first quarter valued at about $320,000. 45.88% of the stock is owned by hedge funds and other institutional investors.
About Histogenics (NASDAQ:HSGX)
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Read More: Moving Average (MA)
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.